Page last updated: 2024-09-04

febuxostat and Hyperlipemia

febuxostat has been researched along with Hyperlipemia in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Elkashef, WF; Heikal, MM; Ibrahim, TM; Shaaban, AA1
AviƱa-Zubieta, JA; Choi, HK; De Vera, MA; McCormick, N; Rai, SK; Sayre, EC; Shojania, K1
Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF1

Trials

1 trial(s) available for febuxostat and Hyperlipemia

ArticleYear
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
    Arthritis research & therapy, 2010, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Drug; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Hyperuricemia; Kidney Diseases; Male; Middle Aged; Obesity; Thiazoles; Treatment Outcome; United States; Uric Acid; Young Adult

2010

Other Studies

2 other study(ies) available for febuxostat and Hyperlipemia

ArticleYear
Effect of febuxostat on biochemical parameters of hyperlipidemia induced by a high-fat diet in rabbits.
    Canadian journal of physiology and pharmacology, 2019, Volume: 97, Issue:7

    Topics: Animals; Biomarkers; Body Weight; Cell Adhesion Molecules; Cytokines; Diet, High-Fat; Febuxostat; Hyperlipidemias; Lipids; Liver; Male; Oxidative Stress; Rabbits

2019
The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012.
    Seminars in arthritis and rheumatism, 2017, Volume: 46, Issue:4

    Topics: Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; British Columbia; Colchicine; Comorbidity; Diabetes Mellitus; Febuxostat; Female; Glucocorticoids; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Incidence; Male; Middle Aged; Population Growth; Prevalence; Probenecid; Sulfinpyrazone; Uricosuric Agents

2017